These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11700581)

  • 21. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.
    Lebel MH; Kellner JD; Ford-Jones EL; Hvidsten K; Wang EC; Ciuryla V; Arikian S; Casciano R
    Clin Infect Dis; 2003 Feb; 36(3):259-68. PubMed ID: 12539065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
    Marchetti M; Colombo GL
    Vaccine; 2005 Aug; 23(37):4565-76. PubMed ID: 15992969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
    Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.
    Silfverdal SA; Berg S; Hemlin C; Jokinen I
    Vaccine; 2009 Mar; 27(10):1601-8. PubMed ID: 19146905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy.
    Merito M; Giorgi Rossi P; Mantovani J; Curtale F; Borgia P; Guasticchi G
    Vaccine; 2007 Jan; 25(3):458-65. PubMed ID: 17049685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy.
    Giorgi-Rossi P; Merito M; Borgia P
    Health Policy; 2009 Feb; 89(2):225-38. PubMed ID: 18639952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative cost effectiveness of varicella, hepatitis A, and pneumococcal conjugate vaccines.
    Jacobs RJ; Meyerhoff AS
    Prev Med; 2001 Dec; 33(6):639-45. PubMed ID: 11716661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pneumococcal vaccination in adults].
    Jonkers RE; Boersma WG
    Ned Tijdschr Geneeskd; 2003 Mar; 147(10):437-41. PubMed ID: 12666513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
    Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
    Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
    Hubben GA; Bos JM; Glynn DM; van der Ende A; van Alphen L; Postma MJ
    Vaccine; 2007 May; 25(18):3669-78. PubMed ID: 17360082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pneumococcal vaccine for the elderly--ineffective but cost-efficient?].
    Håkansson J
    Lakartidningen; 2000 Dec; 97(50):5958. PubMed ID: 11188544
    [No Abstract]   [Full Text] [Related]  

  • 32. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
    López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
    J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects.
    Claes C; Reinert RR; von der Schulenburg JM
    Eur J Health Econ; 2009 Feb; 10(1):25-38. PubMed ID: 18379830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada.
    De Wals P; Robin E; Fortin E; Thibeault R; Ouakki M; Douville-Fradet M
    Pediatr Infect Dis J; 2008 Nov; 27(11):963-8. PubMed ID: 18845982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reducing medical service utilization by encouraging vaccines: randomized controlled trial.
    Berg GD; Thomas E; Silverstein S; Neel CL; Mireles M
    Am J Prev Med; 2004 Nov; 27(4):284-8. PubMed ID: 15488357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness studies of pneumococcal conjugate vaccines.
    McIntosh ED
    Expert Rev Vaccines; 2004 Aug; 3(4):433-42. PubMed ID: 15270648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pneumococcal vaccination in older adults.
    Hirschmann JV
    N Engl J Med; 2003 Aug; 349(7):712-4; author reply 712-4. PubMed ID: 12917315
    [No Abstract]   [Full Text] [Related]  

  • 38. [Prevention of pneumococcal infection by vaccination].
    Bertz H
    Fortschr Med Orig; 2001 Jul; 119 Suppl 2():71-5. PubMed ID: 15704359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increasing pneumococcal vaccination in managed care through telephone outreach.
    Winston CA; Mims AD; Leatherwood KA
    Am J Manag Care; 2007 Oct; 13(10):581-8. PubMed ID: 17927463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults.
    Metlay JP; Fishman NO; Joffe M; Edelstein PH
    Vaccine; 2006 Jan; 24(4):468-75. PubMed ID: 16125826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.